NCT06863662View on ClinicalTrials.gov

Efficacy and Safety of Etoricoxib/Tizanidine Versus Etoricoxib for Acute Low Back Pain Associated to Muscle Spasm

PHASE3RecruitingINTERVENTIONAL
Enrollment

136

Participants

Timeline

Start Date

September 18, 2024

Primary Completion Date

June 30, 2025

Study Completion Date

July 30, 2025

Conditions
Acute Low-back PainMuscle Spasm; Back Pain
Interventions
DRUG

Etoricoxib + Tizanidine fixed dose

One sachet with 120 mg / 4 mg, dissolved in 100 mL of water

DRUG

Etoricoxib fixed dose

One sachet with 120 mg, dissolved in 100 mL of water

Trial Locations (1)

11000

RECRUITING

Laboratorio Silanes, S.A. de C.V., Mexico City

All Listed Sponsors
lead

Laboratorios Silanes S.A. de C.V.

INDUSTRY